PSA Rising

Erectile Function

More Stories

Levitra May Protect the Heart Feb 2006

Two New Erectile Dysfunction Drugs: How They Measure Up Against Viagra Dec 20 2003

High Dose Radiation Effective for Localized Prostate Cancer Oct 21 2003

Importance of Testing PSA Levels During First Months After Radiotherapy: Texas Report Oct 6 2003

Bostwick Laboratories Announces uPM3(TM) Test, First Genetic Test for Prostate Cancer (PSA Rising, Oct 10 20003)

If your brother has prostate cancer, your risk of the disease is nearly tripled Overview study from Fox-Chase Cancer Center. Sept 16, 2003

Racial Difference in Androgen Receptor May Explain Aggressive Prostate Cancer in African-American Men PSA Rising Sept 4 2003

Hormonal Blockade For Prostate Cancer May Cause Rapid Bone Loss full story, June 2001

Study Confirms PSA Test Reduces Prostate Cancer Deaths in Blacks and Whites National Cancer Institute August 30, 2003

Telltale Prostate Cancer Protein Key to Breast Cancer, Too Sept 20, 2003


We subscribe to the HONcode principles.
Verify here.

updated Feb 16, 2006

Viagra Effective Over Long Term For Prostate Cancer Patients Receiving Radiation Therapy

PSA Rising Oct 20, 2003 /ASTRO/ — Viagra effectively treats erectile dysfunction for years after prostate cancer patients receive radiation therapy, according to the first study to look at the effectiveness of the medication in a large number of patients over an extended time period. Four years after undergoing 3-dimensional conformal radiotherapy (3D-CRT) and brachytherapy for prostate cancer, the medication successfully treated ED in seventy-five percent of patients.

The new study was presented today at the American Society for Therapeutic Radiology and Oncology’s Annual Meeting here.

“Other studies have reported on the initial effectiveness of Viagra for prostate cancer patients receiving radiation therapy, but there was scant information on the continued use and effectiveness of the medication for longer periods of time,” said senior author Michael J. Zelefsky, M.D., Chief of Brachytherapy at New York’s Memorial Sloan-Kettering Cancer Center.

The results of the study led by researcher Jianfeng Xu, Ph.D. will be published today in the British Journal of Cancer.

From 1998 to 2002, the trial followed 363 prostate cancer patients at Memorial Sloan-Kettering Cancer Center who received 3D-CRT and brachytherapy. The patients had normal erectile function before therapy, and all experienced some degree of ED after treatment.

Among patients who reported success with the drug after the initial trial, 96 percent continued to use and find the medication effective. Higher external beam radiation doses were associated with decreased efficacy of Viagra.

“The good news for men facing therapy for prostate cancer is that Viagra does not seem to lose its effectiveness over time,” Dr. Zelefsky concluded. “As more younger patients opt for non-surgical approaches, ED is obviously an important issue.”

The paper delivered at ASTRO was called “Prognostic Factors for Maintained Efficacy of Sildenafil Citrate in the Management of Erectile Dysfunction”

The American Society for Therapeutic Radiology and Oncology is the largest radiation oncology society in the world, with 7000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society’s mission is to advance the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.

Source: ASTRO. Edited by J. Strax, PSA Rising. Date posted, October 20, 2003.





Prostate Cancer Awareness Ribbon About Us | Content Policy | Privacy Policy | Contact Us | ©1997- 2006 PSA Rising This Page